Fairvalue-Calculator Fairvalue-Calculator
EN DE

NewMed Energy - Limited (DKDRF) Fair Value & Analysis

Energy · US · Market cap $6.7B

Price$5.52
Fair Value$2.98
Upside-46.0%
Quality95/100
Evidence: High Range $2.00 – $4.75

Analysis

NewMed Energy - Limited (DKDRF) currently trades at $5.52, while our model-based Fair Value estimate is $2.98 — implying the stock looks roughly 46.0% overvalued today. We read business quality at 95/100 (high quality), in the Energy sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).

About the company

NewMed Energy - Limited Partnership exploration, development, production, and marketing of natural gas, condensate, and oil in Israel, Jordan and Egypt. The company holds interests in the Leviathan project, which covers an area of 500 square kilometer (km2) located to the west of the shores of Haifa; the Block 12 that covers an area of approximately 386 km2 located in Cyprus; and the Yam Tethys project, located to the west of the shores of Ashkelon. It also holds interests in the Boujdour Atlantique exploration license that covers an area of approximately 33,815 km2 located in the south of the Moroccan exclusive economic zone; and the Tanin and Karish leases covering an area of approximately 500km2 located to the west of the shores of Nahariya. The company serves independent power producers, marketing companies, and industrial customers, as well as exports natural gas to Jordan and in Egypt. The company was formerly known as Delek Drilling - Limited Partnership and changed its name …

Open the full interactive analysis →

Similar stocks

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.